Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Seasonal influenza vaccination in adults

Patricia L Hibberd, MD, PhD
Section Editor
Martin S Hirsch, MD
Deputy Editor
Anna R Thorner, MD


Influenza is an acute respiratory illness caused by influenza A or B viruses. It occurs in epidemics nearly every year, mainly during the winter season in temperate climates. Influenza viruses change their antigenic characteristics frequently, and their subsequent spread depends upon the susceptibility of the population to viruses with novel antigens. Annual influenza vaccination is an important public health measure for preventing influenza infection [1-3]. The protection provided by influenza vaccines is based upon induction of virus-neutralizing antibodies, mainly against the viral hemagglutinin.

The role of influenza vaccination in the prevention of seasonal influenza will be reviewed here. The use of influenza vaccine in immunocompromised hosts, pregnant women, patients with chronic liver disease, patients with end-stage renal disease, healthcare workers, and travelers is discussed separately. (See associated topic reviews.)

The clinical manifestations and diagnosis of influenza in adults, the role of antiviral agents for the prevention and treatment of seasonal influenza, and vaccines against the 2009 pandemic H1N1 influenza ("swine influenza") virus, H5N1 avian influenza, and H7N9 avian influenza are also reviewed elsewhere. Seasonal influenza vaccination in children is also presented separately. (See "Clinical manifestations of seasonal influenza in adults" and "Diagnosis of seasonal influenza in adults" and "Prevention of seasonal influenza with antiviral drugs in adults" and "Treatment of seasonal influenza in adults" and "Treatment and prevention of pandemic H1N1 influenza ('swine influenza')", section on 'Vaccination' and "Avian influenza vaccines" and "Avian influenza A H7N9: Treatment and prevention", section on 'Vaccine development' and "Seasonal influenza in children: Prevention with vaccines".)


Influenza activity — The United States Centers for Disease Control and Prevention (CDC), in collaboration with the World Health Organization (WHO) and its reporting network, tracks influenza virus isolates throughout the world to monitor disease activity and to predict the appropriate components for the annual influenza vaccine. Surveillance information, which is updated weekly during influenza season, is available on the CDC website. In addition, FluNet, a database for global influenza virus surveillance, is available on the WHO website. The typical seasonal trends of influenza activity in the United States are shown in the following Figure (figure 1).

Indications — In 2010, the United States Advisory Committee on Immunization Practices (ACIP) expanded the recommendation for influenza vaccination to include all individuals six months of age and older [4]. This represented a change from previous guidelines, which recommended influenza vaccination for individuals at increased risk of influenza complications and close contacts of such individuals. High-risk individuals, their close contacts, and healthcare workers should remain high-priority recipients in vaccination campaigns (table 1). (See 'High-priority groups' below.)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Oct 26, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Uyeki TM. Preventing and controlling influenza with available interventions. N Engl J Med 2014; 370:789.
  2. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines. MMWR Recomm Rep 2016; 65:1.
  3. Treanor JJ. CLINICAL PRACTICE. Influenza Vaccination. N Engl J Med 2016; 375:1261.
  4. CDC's Advisory Committee on Immunization Practices (ACIP) recommends universal annual influenza vaccination. http://www.cdc.gov/media/pressrel/2010/r100224.htm (Accessed on May 16, 2010).
  5. Castilla J, Godoy P, Domínguez A, et al. Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza. Clin Infect Dis 2013; 57:167.
  6. Ehrlich HJ, Singer J, Berezuk G, et al. A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clin Infect Dis 2012; 54:946.
  7. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999; 282:137.
  8. Kilbourne ED. Influenza immunity: new insights from old studies. J Infect Dis 2006; 193:7.
  9. United States Centers for Disease Control and Prevention. Seasonal influenza vaccine safety: a summary for clinicians. http://www.cdc.gov/flu/professionals/vaccination/vaccine_safety.htm (Accessed on March 14, 2012).
  10. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2016 southern hemisphere influenza season. http://www.who.int/influenza/vaccines/virus/recommendations/2016_south/en/ (Accessed on December 15, 2015).
  11. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2016-2017 northern hemisphere influenza season. http://www.who.int/influenza/vaccines/virus/recommendations/2016_17_north/en/ (Accessed on June 06, 2016).
  12. Hensley SE, Das SR, Bailey AL, et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 2009; 326:734.
  13. Heikkinen T, Ikonen N, Ziegler T. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012. Clin Infect Dis 2014; 59:1519.
  14. US Food and Drug Administration. FDA updated communication on use of jet Injectors with inactivated influenza vaccines. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm276773 (Accessed on August 21, 2014).
  15. Centers for Disease Control and Prevention (CDC). Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use - United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:485.
  16. FDA news release. FDA approves first seasonal influenza vaccine containing an adjuvant. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474295.htm (Accessed on November 25, 2015).
  17. US Food and Drug Administration. May 9, 2011. Approval Letter - Fluzone Intradermal. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm255160.htm (Accessed on May 24, 2011).
  18. Sanofi Pasteur Press Release. FDA Licenses Sanofi Pasteur’s New Influenza Vaccine Delivered by Intradermal Microinjection. http://multivu.prnewswire.com/mnr/sanofipasteur/49833/ (Accessed on May 24, 2011).
  19. Sanofi Pasteur announces FDA approval of Fluzone intradermal quadrivalent (influenza vaccine) for adults. http://sanofipasteurus.mediaroom.com/2014-12-12-Sanofi-Pasteur-Announces-FDA-Approval-of-Fluzone-Intradermal-Quadrivalent-Influenza-Vaccine-for-Adults (Accessed on January 04, 2015).
  20. US Food and Drug Administration. FDA news release. FDA approves first seasonal influenza vaccine manufactured using cell culture technology. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm (Accessed on November 26, 2012).
  21. Flucelvax prescribing information. www.novartisvaccinesdirect.com/pdf/Flucelvax_PI.pdf (Accessed on November 28, 2012).
  22. US Food and Drug Administration. FDA news release. FDA approves new seasonal influenza vaccine made using novel technology www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.htm (Accessed on January 17, 2013).
  23. US Food and Drug Administration. October 29, 2014 Approval Letter - Flublok. Accelerated supplement approval. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm421396.htm (Accessed on November 03, 2014).
  24. Flublok Quadrivalent (influenza vaccine) - Prescribing information. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM524684.pdf (Accessed on October 21, 2016).
  25. Centers for Disease Control and Prevention. ACIP votes down use of LAIV for 2016-2017 flu season. http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html (Accessed on June 24, 2016).
  26. Sibley WA, Bamford CR, Laguna JF. Influenza vaccination in patients with multiple sclerosis. JAMA 1976; 236:1965.
  27. Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2014; :CD001269.
  28. Moura FE. Influenza in the tropics. Curr Opin Infect Dis 2010; 23:415.
  29. National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.
  30. Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007; 55:1499.
  31. National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.
  32. Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol 2007; 28:702.
  33. Bateman AC, Kieke BA, Irving SA, et al. Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season. J Infect Dis 2013; 207:1262.
  34. Ahmed AE, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. Lancet 1995; 346:591.
  35. Voordouw AC, Sturkenboom MC, Dieleman JP, et al. Annual revaccination against influenza and mortality risk in community-dwelling elderly persons. JAMA 2004; 292:2089.
  36. Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009; 199:159.
  37. Centers for Disease Control and Prevention (CDC). Health Alert Network. CDC health advisory regarding the potential for circulation of drifted influenza A (H3N2) viruses. http://emergency.cdc.gov/han/han00374.asp (Accessed on December 05, 2014).
  38. Centers for Disease Control and Prevention. Seasonal influenza vaccine effectiveness, 2005-2015. http://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm (Accessed on August 03, 2015).
  39. Kwong JC, Maaten S, Upshur RE, et al. The effect of universal influenza immunization on antibiotic prescriptions: an ecological study. Clin Infect Dis 2009; 49:750.
  40. Center for Infectious Disease Research & Policy. The compelling need for game-changing influenza vaccines an analysis of the influenza vaccine enterprise and recommendations for the future. http://www.cidrap.umn.edu/cidrap/files/80/ccivi%20report.pdf (Accessed on January 10, 2013).
  41. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36.
  42. Ohmit SE, Petrie JG, Malosh RE, et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 2013; 56:1363.
  43. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319.
  44. McLean HQ, Thompson MG, Sundaram ME, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis 2014; 59:1375.
  45. Ohmit SE, Petrie JG, Malosh RE, et al. Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility. J Infect Dis 2015; 211:1519.
  46. Skowronski DM, Chambers C, Sabaiduc S, et al. A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season. Clin Infect Dis 2016; 63:21.
  47. Neuzil KM. How can we solve the enigma of influenza vaccine-induced protection? J Infect Dis 2015; 211:1517.
  48. Treanor JJ, Szilagyi P. Editorial commentary: influenza vaccine: glass half full or half empty? Clin Infect Dis 2013; 56:1370.
  49. Grijalva CG, Zhu Y, Williams DJ, et al. Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination. JAMA 2015; 314:1488.
  50. Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ 2010; 182:1617.
  51. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009; 200:841.
  52. Reisinger KS, Block SL, Izu A, et al. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009; 200:849.
  53. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51:997.
  54. Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011; 377:751.
  55. Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007; 297:1577.
  56. Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733.
  57. Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169:68.
  58. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355:2513.
  59. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361:1260.
  60. Wang Z, Tobler S, Roayaei J, Eick A. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 2009; 301:945.
  61. Phillips CJ, Woolpert T, Sevick C, et al. Comparison of the effectiveness of trivalent inactivated influenza vaccine and live, attenuated influenza vaccine in preventing influenza-like illness among US military service members, 2006-2009. Clin Infect Dis 2013; 56:11.
  62. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351:2286.
  63. Kenney RT, Frech SA, Muenz LR, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351:2295.
  64. Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin Infect Dis 2010; 50:1331.
  65. Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198:650.
  66. McAllister L, Anderson J, Werth K, et al. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial. Lancet 2014; 384:674.
  67. Sprenger MJ, Mulder PG, Beyer WE, et al. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989. Int J Epidemiol 1993; 22:334.
  68. Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994; 272:1661.
  69. Edmondson WP Jr, Rothenberg R, White PW, Gwaltney JM Jr. A comparison of subcutaneous, nasal, and combined influenza vaccination. II. Protection against natural challenge. Am J Epidemiol 1971; 93:480.
  70. Rudenko LG, Arden NH, Grigorieva E, et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 2000; 19:308.
  71. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331:778.
  72. Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007; 357:1373.
  73. Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348:1322.
  74. Mangtani P, Cumberland P, Hodgson CR, et al. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis 2004; 190:1.
  75. Armstrong BG, Mangtani P, Fletcher A, et al. Effect of influenza vaccination on excess deaths occurring during periods of high circulation of influenza: cohort study in elderly people. BMJ 2004; 329:660.
  76. Monto AS, Rotthoff J, Teich E, et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis 2004; 39:459.
  77. Jackson ML, Nelson JC, Weiss NS, et al. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 2008; 372:398.
  78. Talbot HK, Griffin MR, Chen Q, et al. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J Infect Dis 2011; 203:500.
  79. Kwong JC, Campitelli MA, Gubbay JB, et al. Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among elderly adults during the 2010-2011 season. Clin Infect Dis 2013; 57:820.
  80. Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. Lancet Infect Dis 2014; 14:1228.
  81. Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002; 35:370.
  82. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999; 130:397.
  83. Herzog NS, Bratzler DW, Houck PM, et al. Effects of previous influenza vaccination on subsequent readmission and mortality in elderly patients hospitalized with pneumonia. Am J Med 2003; 115:454.
  84. Jefferson T, Di Pietrantonj C, Al-Ansary LA, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010; :CD004876.
  85. Wong K, Campitelli MA, Stukel TA, Kwong JC. Estimating influenza vaccine effectiveness in community-dwelling elderly patients using the instrumental variable analysis method. Arch Intern Med 2012; 172:484.
  86. Chen Q, Griffin MR, Nian H, et al. Influenza vaccine prevents medically attended influenza-associated acute respiratory illness in adults aged ≥50 years. J Infect Dis 2015; 211:1045.
  87. Fry AM, Kim IK, Reed C, et al. Modeling the effect of different vaccine effectiveness estimates on the number of vaccine-prevented influenza-associated hospitalizations in older adults. Clin Infect Dis 2014; 59:406.
  88. Black S, Nicolay U, Del Giudice G, Rappuoli R. Influence of Statins on Influenza Vaccine Response in Elderly Individuals. J Infect Dis 2016; 213:1224.
  89. Omer SB, Phadke VK, Bednarczyk RA, et al. Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness. J Infect Dis 2016; 213:1216.
  90. McLean HQ, Chow BD, VanWormer JJ, et al. Effect of Statin Use on Influenza Vaccine Effectiveness. J Infect Dis 2016; 214:1150.
  91. Simonsen L, Taylor RJ, Viboud C, et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7:658.
  92. Groenwold RH, Hoes AW, Hak E. Impact of influenza vaccination on mortality risk among the elderly. Eur Respir J 2009; 34:56.
  93. Eurich DT, Marrie TJ, Johnstone J, Majumdar SR. Mortality reduction with influenza vaccine in patients with pneumonia outside "flu" season: pleiotropic benefits or residual confounding? Am J Respir Crit Care Med 2008; 178:527.
  94. Jackson LA. Benefits of examining influenza vaccine associations outside of influenza season. Am J Respir Crit Care Med 2008; 178:439.
  95. Brookhart MA, McGrath L. The influenza vaccine in elderly persons: a shot in the dark? Arch Intern Med 2012; 172:492.
  96. Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 2008; 197:490.
  97. Song JY, Cheong HJ, Hwang IS, et al. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. Vaccine 2010; 28:3929.
  98. Castilla J, Martínez-Baz I, Martínez-Artola V, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 2013; 18.
  99. Falsey AR, Treanor JJ, Tornieporth N, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172.
  100. Nace DA, Lin CJ, Ross TM, et al. Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities. J Infect Dis 2015; 211:1915.
  101. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014; 371:635.
  102. Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis 2015; 15:293.
  103. Richardson DM, Medvedeva EL, Roberts CB, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans. Clin Infect Dis 2015; 61:171.
  104. Chit A, Becker DL, DiazGranados CA, et al. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial. Lancet Infect Dis 2015; 15:1459.
  105. Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med 2010; 363:2036.
  106. Black S. Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults. Vaccine 2015; 33 Suppl 2:B3.
  107. De Donato S, Granoff D, Minutello M, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999; 17:3094.
  108. O'Hagan DT, Rappuoli R, De Gregorio E, et al. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 2011; 10:447.
  109. Talbot HK, Nian H, Zhu Y, et al. Clinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adults. Clin Infect Dis 2015; 60:1170.
  110. Hung IF, Leung AY, Chu DW, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis 2010; 51:1007.
  111. King JC Jr, Stoddard JJ, Gaglani MJ, et al. Effectiveness of school-based influenza vaccination. N Engl J Med 2006; 355:2523.
  112. Hurwitz ES, Haber M, Chang A, et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 2000; 284:1677.
  113. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000; 284:1655.
  114. Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin Infect Dis 2001; 33:1879.
  115. Lee PY, Matchar DB, Clements DA, et al. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002; 137:225.
  116. Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005; 118:68.
  117. Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121:947.
  118. Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial. Arch Intern Med 1996; 156:1546.
  119. Skowronski DM, Strauss B, De Serres G, et al. Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event? Clin Infect Dis 2003; 36:705.
  120. Moro PL, Arana J, Cano M, et al. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010. Clin Infect Dis 2012; 54:1608.
  121. Sanofi pasteur. Fluzone intradermal. Highlights of prescribing information. http://www.fda.gov/downloads/biologicsbloodvaccines/.../ucm195479.pdf (Accessed on September 30, 2013).
  122. Young F, Marra F. A systematic review of intradermal influenza vaccines. Vaccine 2011; 29:8788.
  123. Harper SA, Fukuda K, Cox NJ, et al. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003; 52:1.
  124. Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005; 294:2720.
  125. FluMist quadrivalent (influenza vaccine live, intranasal) intranasal spray, 2016-2017 formula. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM294307.pdf (Accessed on August 30, 2016).
  126. Neuzil KM, Bright RA. Influenza vaccine manufacture: keeping up with change. J Infect Dis 2009; 200:835.
  127. Glezen WP. Cell-culture-derived influenza vaccine production. Lancet 2011; 377:698.
  128. Lillie PJ, Berthoud TK, Powell TJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012; 55:19.
  129. Gerhard W, Mozdzanowska K, Zharikova D. Prospects for universal influenza virus vaccine. Emerg Infect Dis 2006; 12:569.
  130. Wei CJ, Boyington JC, McTamney PM, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010; 329:1060.
  131. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010; 16:1389.
  132. Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850.
  133. Russell CJ. Stalking influenza diversity with a universal antibody. N Engl J Med 2011; 365:1541.
  134. Miller MS, Tsibane T, Krammer F, et al. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis 2013; 207:98.
  135. Yassine HM, Boyington JC, McTamney PM, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 2015; 21:1065.
  136. Impagliazzo A, Milder F, Kuipers H, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 2015; 349:1301.
  137. Berthoud TK, Hamill M, Lillie PJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011; 52:1.
  138. Hambleton S. Editorial commentary: a better grip: T cells strengthen our hand against influenza. Clin Infect Dis 2011; 52:8.
  139. Wrammert J, Koutsonanos D, Li GM, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208:181.
  140. Engler RJ, Nelson MR, Klote MM, et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med 2008; 168:2405.